Janikova Andrea, Bortlicek Zbynek, Campr Vit, Kopalova Natasa, Benesova Katerina, Hamouzova Jitka, Belada David, Prochazka Vit, Pytlik Robert, Vokurka Samuel, Pirnos Jan, Duras Juraj, Mocikova Heidi, Mayer Jiri, Trneny Marek
a Department of Internal Medicine, Hematology and Oncology , Masaryk University and University Hospital Brno , Brno , Czech Republic .
b Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University , Brno , Czech Republic .
Leuk Lymphoma. 2016 May;57(5):1094-103. doi: 10.3109/10428194.2015.1079313. Epub 2015 Oct 12.
Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to RCHOP induction and a comparison of two different RM schedules (RM8=eight doses given every 3 months and RM12=12 doses given every 2 months). A total of 183 patients received RM and 136 patients were observed; 5-year PFS was better in the RM arm, 74.1% vs 52.3% (p<0.001), which was projected in 5-year OS 93.8% vs 87.5% (p=0.005). However, 5-year PFS was similar in both the RM8 (n=54) and RM12 (n=56) arms. In the first line, RM significantly prolongs PFS and OS in FL, but different RM schedules bring a similar benefit.
利妥昔单抗维持治疗（RM）可改善晚期滤泡性淋巴瘤（FL）的无进展生存期（PFS），但不同RM方案的影响尚不清楚。本研究对319例接受RCHOP诱导治疗有效的未经治疗的FL患者（II-IV期；1-3A级）进行了长达2年的RM治疗与观察的回顾性评估，并比较了两种不同的RM方案（RM8 = 每3个月给药8剂和RM12 = 每2个月给药12剂）。共有183例患者接受了RM治疗，136例患者接受了观察；RM组的5年PFS更好，分别为74.1%和52.3%（p<0.001），预计5年总生存期（OS）分别为93.8%和87.5%（p = 0.005）。然而，RM8组（n = 54）和RM12组（n = 56）的5年PFS相似。在一线治疗中，RM可显著延长FL患者的PFS和OS，但不同的RM方案带来的益处相似。
